PWS
ABBV icon

Peloton Wealth Strategists’s AbbVie ABBV Stock Holding History

Peloton Wealth Strategists’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.21M Sell
12,775
-150
-1% -$32.3K 1.19% 32
2026
Q1 		$2.81M Sell
12,925
-150
-1% -$33.3K 1.14% 36
2025
Q4 		$2.99M Sell
13,075
-450
-3% -$103K 1.16% 30
2025
Q3 		$3.13M Sell
13,525
-155
-1% -$31.6K 1.23% 27
2025
Q2 		$2.54M Sell
13,680
-1,700
-11% -$316K 1.02% 37
2025
Q1 		$3.22M Sell
15,380
-7,000
-31% -$1.36M 1.35% 27
2024
Q4 		$3.98M Sell
22,380
-35
-0.2% -$6.43K 1.6% 22
2024
Q3 		$4.43M Sell
22,415
-2,285
-9% -$426K 1.76% 18
2024
Q2 		$4.24M Sell
24,700
-135
-0.5% -$22.4K 1.74% 20
2024
Q1 		$4.52M Sell
24,835
-170
-0.7% -$29.3K 1.84% 18
2023
Q4 		$3.88M Sell
25,005
-2,090
-8% -$305K 1.68% 23
2023
Q3 		$4.04M Sell
27,095
-14,380
-35% -$2.11M 1.86% 20
2023
Q2 		$5.59M Sell
41,475
-2,150
-5% -$315K 2.47% 10
2023
Q1 		$6.95M Sell
43,625
-80
-0.2% -$12.2K 3.18% 3
2022
Q4 		$7.06M Sell
43,705
-1,600
-4% -$245K 3.4% 3
2022
Q3 		$6.08M Sell
45,305
-65
-0.1% -$9.33K 3.16% 2
2022
Q2 		$6.95M Sell
45,370
-2,759
-6% -$422K 3.39% 2
2022
Q1 		$7.8M Sell
48,129
-380
-0.8% -$55.2K 3.26% 4
2021
Q4 		$6.57M Sell
48,509
-580
-1% -$68.5K 2.63% 5
2021
Q3 		$5.29M Sell
49,089
-1,960
-4% -$224K 2.17% 16
2021
Q2 		$5.75M Buy
51,049
+3,200
+7% +$360K 2.37% 12
2021
Q1 		$5.18M Buy
47,849
+1,176
+3% +$126K 2.43% 13
2020
Q4 		$5M Buy
46,673
+700
+2% +$67.3K 2.48% 13
2020
Q3 		$4.03M Buy
45,973
+1,510
+3% +$142K 2.26% 14
2020
Q2 		$4.37M Buy
44,463
+18,483
+71% +$1.63M 2.75% 7
2020
Q1 		$1.98M Buy
25,980
+9,268
+55% +$789K 1.61% 27
2019
Q4 		$1.48M Buy
16,712
+1,150
+7% +$95.5K 0.9% 45
2019
Q3 		$1.18M Buy
+15,562
New +$1.07M 0.75% 51

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Peloton Wealth Strategists's ABBV Position: Q2 2026 in Review

Peloton Wealth Strategists reduced its AbbVie (ABBV) stake by 1.2% in Q2 2026, selling an estimated $32.3K and leaving 12,775 shares worth $3.21M. The position accounts for 1.19% of the portfolio, ranked #32.

Peloton Wealth Strategists first reported a position in ABBV in Q3 2019 and has held it in 28 quarters since. The position peaked at $7.8M in Q1 2022. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Peloton Wealth Strategists held 12,775 shares of AbbVie worth $3.21M as of Q2 2026.
  • Peloton Wealth Strategists sold 150 AbbVie shares in Q2 2026, an estimated $32.3K.
  • AbbVie made up 1.19% of Peloton Wealth Strategists's portfolio in Q2 2026, its #32 holding.
  • Peloton Wealth Strategists first reported a position in AbbVie in Q3 2019 and has held it in 28 quarters since.
  • Peloton Wealth Strategists's AbbVie position peaked at $7.8M in Q1 2022.
  • 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Peloton Wealth Strategists's 13F filing for Q2 2026, filed 10 Aug 2026.